



CONNECTPRENEUR INVESTOR NETWORK: VIRTUAL MEETING

Curated Presenters.
Investors Only.

October 30, 2025
11am – 12pm ET

CONNECTpreneur.org

AGENDA

11:00 - 11:05 AM

MEETING OPENS & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community
- SKYLAR RALLISON, Community Manager, CONNECTpreneur

11:05 - 11:35 AM

PITCH SESSIONS

Companies will be introduced by:

SARA CLASPER, Associate Attorney, NEXT powered by
Shulman Rogers

11:35 - 12:00 PM

PRESENTING COMPANY BREAKOUT ROOMS

Q & A Time

PRESENTING COMPANIES



A28 Therapeutics – Stanley Lewis



AirLift – Alex Alexanian



BetterSeeds – Ido Margalit



Meiogenix – Ricardo Garcia de Alba



Odnass – Velimir Pajic



Solaris Endovascular – Randy Hubbel



SPACELING – Michael Sperling

SPEAKERS



TIEN WONG, CEO, OPUS8, INC. @tienwong

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.



Stanley Lewis
Phone: (713) 252-2619
Email: Stanley.Lewis@A28Therapeutics.com

Value Proposition: A28 Therapeutics is advancing AT-101, a first-in-class Targeted Oncolytic Peptide (TOP) addressing the unmet need in liver cancer and liver metastases. AT-101 combines a hormone receptor targeting unit with an oncolytic peptide to selectively disrupt cancer cell membranes resulting in rapid, immunogenic cell death while sparing healthy tissue. The TOPs platform is the next generation in targeted therapy for cancer.

Company Background: Founded in 2021, A28 Therapeutics is a privately held, clinical-stage biopharmaceutical company advancing a platform to deliver drugs for targeted killing of cancer cells. The first development candidate from this platform, AT-101, has demonstrated remarkable tolerability and anti-cancer activity in two clinical trials. The company's Seed financing will support additional preclinical testing in hepatocellular carcinoma (HCC), regulatory and legal filings, and manufacturing in preparation for a dose-optimization and proof-of-concept clinical trial.

Leadership Team: Stanley Lewis, MD, MPH – Founder & CEO has over 25 years leading biotechnology drug development (Phases 1-4), fundraising (over \$100M), and company building. A28 Therapeutics has assembled a team of drug development experts with over 75 years of drug development experience, multiple drug approvals, IPOs, and commercial experience. Scientific and Business advisors include executives who have completed multi-billion-dollar M&A exits in just the last three years.

Products/Services: AT-101 demonstrated a 69% objective response rate (ORR) in ovarian cancer patients with liver metastases compared to a 17% ORR for standard-of-care alone, while also increasing overall survival by 61%. A unique biodistribution and residency in the liver, and highly predictive, CLIA-certified biomarker assay allows for precision in patient selection to optimize outcomes.

Technologies/Special Know-How: Targeted Oncolytic Peptides (TOPs) combine a targeting peptide (less expensive to manufacture than antibodies) with a cancer specific payload for optimal, specific, tumor-killing without harming healthy cells. TOPs can be developed for known or novel targets, expanding the range of potential treatments for different cancer types.

Market: Initial target indications are hepatocellular carcinoma and ovarian cancer with liver metastases (15K & 6K US patients, respectively). Combined global peak revenue potential exceeds \$4B annually. Revenue model includes commercialization partnerships with pharmaceutical companies and milestone-based licensing.

Distribution Channels: Traditional pharmaceutical sales including direct engagement with academic and community oncology centers; strategic partnerships with leading international biopharma companies; future distribution through specialty oncology networks.

Competition: Compared to Antibody Drug Conjugates (ADCs), AT-101 has no need to engineer a linker to a cytotoxic payload, thus avoiding manufacturing complexity and potential toxicities. AT-101 is also ideal for combination therapy with other cancer treatments as the remarkable tolerability profile limits drug-drug interactions or overlapping toxicities and the unique mechanism of action creates synergy with other treatments. Unlike popular cancer therapies such as immune checkpoints, ADCs, cell & gene therapies and oncolytic viruses, AT-101 has low COGs and low immunogenicity.

Quick Facts

Company Name:

A28 Therapeutics, Inc.

Contact:

Stanley Lewis, Founder & CEO

Address:

7660 Fay Avenue H829
La Jolla, CA 92037

Phone:

(713) 252-2619

Email:

Stanley.Lewis@A28Therapeutics.com

Website:

<https://a28therapeutics.com/>

Industry:

Biotechnology/Oncology

Bank:

Silicon Valley Bank/First Citizens

Law Firm:

VLP Law/Wilson-Sonsini

Patents:

26 issued; several pending

Number of Employees:

5 (incl. contingent/fractional)

Leadership Team:

Rhonda Wallen, Philip Vorhies,
Thomas Duensing, Carola
Leuschner

Amount of Financing Sought:

\$5M

Current Investors

Mind Fund

Use of Funds:

Manufacturing, preclinical, legal &
regulatory filings



Blissera Corp. (dba AirLift)
 1185 Campbell Ave., #G1,
 San Jose, CA 95126, USA
 toll Free: +1.844.960.4141
 fax: +1.408.982.3383
www.blissera.com

Executive Summary

Sep, 2025

About:

Incorporated: Delaware: 2019; California: 2021
 Business Type: high-end consumer product manufacturer in vertical mobility
 Business model: manufacturing, installation and maintenance of high-end residential and commercial elevators for low-rise homes, apartments, offices, business centers, hotels, malls, airports
 Technology: uses vacuum forces to lift a glass-made cabin in a glass shaft – a disruptive vertical hyperloop technology, exceeds competition in aesthetics, footprint, safety and performance by 3-5x
 IP: US patents granted, EU allowed, China and Japan pending, trademark allowed

Leadership Team:

Alex Alexanian: Founder and CEO, BOD. Successful multiple exits in previous high-tech endeavors
 Arra Yerganian: BOD. Executive positions with the largest homebuilders Lennar and Pulte Homes
 Greg Porter: BOD. Gen partner, Porter Ventures, founder of PowerSchool (PWSC \$3.8B)
 Dan Maydan: Strategic Advisor, built Applied Materials \$0-\$10B+ revenue (AMAT \$124.5B)
 Sean Cross: Strategic Advisor, co-founder of Infinite Reality (\$15.5B market cap)

Products/Services:

Products: Kilimanjaro – luxury residential series, 1000lb load, 4-stops, automated, ADA. Beta – Dec'2025
 Montblanc – budget residential series, 450lb load, 2-stops, manual. Beta – Dec'2027
 Everest and Olympus – commercial series, details to be released later
 Product Price: \$40K – \$100K+ for residential models. Commercial models pricing TBD
 Services: installation, maintenance – variable, mostly outsourced
 Gross margins: 50-60%+ after all-inclusive manufacturing, distribution and installation costs
 LPC: \$90K-\$120K lifetime profit per customer (incl. installation and maintenance over 20-year lifetime)

Business: preorders: 1000+ units worth \$100M+ in contract negotiations ahead of product release

Market: current home elevator market forecasted (by [Fortune Business Insights](#), by [Industry ARC](#)) to reach \$100B by 2031 with CAGR 7.5%. We intend to become a major home elevator vendor and untap into the hidden market of over \$1T – a personal elevator in every multi-story home

Terms of financing:

Financing type: convertible notes, raising \$10M (contact the company for details)
 Funds raised: \$2.6M raised, \$1.5M committed, \$MM in negotiations
 QSBS offering: qualifies for QSBS and section 1244 of the tax code

Use of Funds:

Product: Kilimanjaro – the luxury residential model scheduled for beta release in Dec'2025
 Showrooms: Building showrooms in San Jose and Beverly Hills, CA. Launching in Q1'2026
 Sales:

Year	2025	2026	2027	2028	2029	2030	2031
Orders (#)	2	46	326	1,528	5,048	12,992	20,324
Revenue (\$K)	\$0	\$3,158	\$16,215	\$67,805	\$214,142	\$625,810	\$1,151,943
Gross Margins (%)	0.0%	54.6%	55.4%	57.9%	58.9%	59.7%	61.2%
EBITDA (\$K)	(\$779)	(\$2,816)	(\$1,546)	\$11,665	\$47,498	\$159,351	\$328,895
Projected Market Value (PMV, \$M)	\$41.2 M	\$213.7 M	\$378.8 M	\$610.8 M	\$1206.5 M	\$2539.5 M	\$4579.8 M

BetterSeeds

Ido Margalit, CEO
Email: Ido.margalit@betterseeds.com
Web Address: www.BetterSeeds.com



BETTERSEEDS

Democratizing Gene Editing

Key Management:

Ido Margalit, CEO
Dr. Tal Sherman, CTO
Dr. Shira Corem, VP R&D
Ilanit Madari, CFO

Board:

Chairman: Dr. Helmut Schramm -
Former President at Bayer
CropScience
Board member: Rami Dar, former
Seeds executive at Limagrain

Industry:

Agricultural Biotechnology, Plant
Genetics, Gene Editing

Comemrcial Partners:

Corteva, Syngenta, Bayer, Merck

Current Investors:

\$18.7M Previously Raised.
Backed by 3 venture capital funds

Use of Funds:

Expand commercial team, monetize
small CRISPR technology,
commercialize EDGE delivery
platform, expand sales of traits in
field crops, and general corporate
expenses.

Business Description: Traditional plant gene editing based on 1st-gen CRISPR is costly and hard to use which is why the thousands of small seeds companies avoid its use. BetterSeeds offers a comprehensive solution for all these companies with its 2nd-gen CRISPR tools, which are smaller, more affordable & efficient and easier to use, as well as the only full climate resiliency trait platform. With the upcoming CRISPR deregulation in 2026, BetterSeeds' technology is the only one poised to meet the immense demand for gene editing technology and traits and addresses the critical bottlenecks of 1st-gen CRISPR technology while providing solutions for drought, heat, and pest resistance.

Company Background: BetterSeeds is the only plant genetics biotech with 2nd-gen small CRISPRs (Cas12I and TnpB) and the only CRISPR delivery platform that enables CRISPR application across all crops at less than 50% of the current costs, as well as a complete set of traits. The company has received multiple recognitions including EU Seal of Excellence (2025), selection as UN WIPO GREEN key technology for climate change (2025), Top 12 innovator (2024), and Top 15 CRISPR company (2021). With strong IP portfolio of 42 proprietary patents and 100 licensed patents, BetterSeeds has achieved \$1.8M revenue YTD, already surpassing projected \$1.55M.

Key Management:

Ido Margalit – CEO & Co-founder: 27 years of experience as executive manager in Agritech, formerly BizDev manager at Syngenta, 2nd time founder.

Dr. Tal Sherman – CTO & Co-founder: 12 years of experience in plant breeding and R&D, formerly traits project head at Syngenta.

Ilanit Madari – CFO & HR: 28 years of experience in finance management at numerous startups.

Dr. Shira Corem – VP R&D: 15 years of experience in plant research management and genome editing.

Products/Services: BetterSeeds offers three core products: **(1)** Two small CRISPRs - Cas12I and TnpB **(2)** EDGE™ - engineered viral vectors for efficient delivery of gene editing across all crops, reducing costs and time by >50% versus 1st generation CRISPR; **(3)** Climate resiliency trait platform addressing drought, heat, and pests applicable to all field crops.

These are licensed as a bundle to all seeds companies in exchange for license fees and royalties.

Technologies/Special Know-how: BetterSeeds holds a strong defensible IP portfolio including 42 proprietary patents and 100 licensed patents that cover its small CRISPRs, EDGE nuclease delivery and the traits. Scientific advisory board includes CRISPR pioneer Prof. Virginijus Šikšnys.

Market: The global gene edited seeds market is projected to reach \$80B by 2034 (6.6% CAGR), growing from \$45B in 2025. The 2026 EU approval of gene editing regulations will drive all seed companies to adopt gene editing technology. BetterSeeds targets potential revenue of \$0.6B from licensing products to seed companies globally.

Distribution Channels:

BetterSeeds licenses its technology bundle to seed companies worldwide through a tiered approach: Tier 1 partners (3-5 strategic partners representing ~70% of market) for validation and market influence, Tier 2 partners (dozens of companies, ~10% of market), and remaining thousands of smaller seed companies (~20% of market). Revenue model includes a Phase 1 licensing fees and Phase 2 performance-based royalties.

Competition: Key competitors include Inari, Pairwise and Cibus that rely on 1st-gen CRISPR technology without comparable delivery platforms or trait portfolios.

Financial Projections (Unaudited):

\$ in 000's	2025	2026	2027	2028	2029
Revenue:	\$1,550	\$1,870	\$2,533	\$6,269	\$12,430
EBITDA:	\$(2,352)	\$(2,936)	\$(2,884)	\$68	\$5,150

Meiogenix
Ricardo Garcia de Alba
9 Laboratory Drive, Suite 267
DURHAM NC 27709
Phone: +1 317 418 5251
Email: ricardo@meiogenix.com

Web Address: www.meiogenix.com

Management:

*Ricardo Garcia de Alba, CEO
 Virginie Alexanian, CFO
 Gaganpreet Sidhu, CTO
 Mary Beth Miranda, CBDO*

Industry: *AgTech - Breeding Technologies*

Number of Employees: *14*

Bank: *BNP Paribas - FR
 Silicon Valley Bank – US
 BREX - US*

Auditor: *LCA Auditors - FR*

Law Firm:

McDermott & Emery - FR & US

Amount of Financing Sought:
\$17M equity

Current Investors:

*(\$27M Invested to date)
 Sofinnova, BPI France, Genoa
 Ventures, Casdin Capital,
 Alexandria Ventures*

Use of Funds:

Consolidate value demonstration through commercial partnerships to have first product in pre-launch stage. Continued IP and technology advancement with regulatory readiness in key markets.

Business Description: *Meiogenix advances crop improvement through proprietary breeding technologies based on precise, targeted recombination.*

By unlocking the natural genetic diversity of crops, we enable breeders to deliver differentiated elite varieties that help farmers overcome productivity, sustainability and disease resilience challenges to meet the growing needs for Food, Feed, Fuel and Fiber.

Company Background:

The company has achieved proof of concept in key crops like rice, tomato, and corn, secured over 30 patents, and obtained USDA confirmation that its tomato variety is not regulated as GMO.

Management:

***Ricardo Garcia de Alba, CEO:** Seasoned Leader with over 25 years of experience in Corteva, DuPont, Pioneer Seeds and Procted and Gamble
Virginie Alexanian, CFO: Former Deputy CFO at Collectis, Senior Manager, Deloitte
Gaganpreet Sidhu, CTO: Recognized as one of the world experts in applied meiotic recombination through her work in Meiogenix, Cornell and Columbia
Mary Beth Miranda, CBDO: Experienced Leader with former Business Development, Ventures & Licensing responsibilities at Brightseed, Syngenta & Novonosis*

Products/Services: *Meiogenix has a dual business model that can be applied to a broad set of partners and crops:*

- 1. Technology platform licensing to partners for broad application for crop improvement. Value Capture: License & Milestone Fees + Royalties*
- 2. Unlocked Trait out-licensing to partners with elite products. Value: Trait Unlocking Fees + Royalties*

Technologies/Special Know-how: *Meiogenix AI-driven platform directs meiotic recombination at specific genomic sites, accessing previously unavailable genetic traits without introducing foreign DNA, thus avoiding linkage drag and simplifying regulatory pathways. This approach addresses critical limitations in conventional breeding and gene editing.*

Market: *Meiogenix can enable over 20% growth in today's \$75B Seeds & Trait Market by uncovering more than \$15B opportunities for seed & trait companies.*

Distribution Channels: *Meiogenix has a dual Go-to-Market through partnerships managed with internal direct business development and commercial resources:*

- Technology license provider to selected partners for broad technology application in their elite products*
- Unlocked trait out-licensing to seed partners with elite product.*

Competition: *Meiogenix main direct competition is conventional breeding practices and reluctance to new technology acceptance / adoption. Gene Editing is a complementary technology and can also be an indirect substitute on precise and simple edits to genomes but that does not stimulate targeted and precise recombination without unintended mutations as Meiogenix technology does.*

Financial Projections (Unaudited):

USD \$ MM's	2025	2026	2027	2028
Revenue:	\$ 0.4	\$ 1.0	\$ 2.0	\$ 4.0

Cash & Profit Breakeven planned in 2031/2032



Odnass Pty Ltd – Investor Executive Summary

Redefining Early Cancer Screening

Odnass Pty Ltd is transforming early cancer detection through direct cfDNA quantification from plasma; a rapid, affordable, and scalable method integrated with Artificial Intelligence (AI), Graph Neural Networks (GNN), and Blockchain. It enables multi-cancer detection at the non-symptomatic stage, reducing total operational time (TOT) to under 3 hours and cost to below US \$100 per test, unlocking accessibility for global mass screening.

Value Proposition

A fast, affordable, and secure blood-based multi-cancer screening test that detects early neoplastic changes directly from plasma without sequencing or complex extraction. Odnass combines simplified cfDNA quantification with AI/GNN analytics and blockchain data security, offering unmatched accessibility, scalability, and diagnostic speed.

Company Background

Founded in Perth, Australia, Odnass is a MedTech and AI biotechnology company developing breakthrough early detection systems. Patent AU 2025902937 was filed in July 2025. Laboratory and validation infrastructure are established to commence Proof-of-Concept trials in Q4 2025 (Oct-Dec).

Leadership Team

Dr Velimir Pajic, CEO & Co-Founder; medical scientist with 25+ years R&D experience and founder of Liquim Ltd and Ardaei Institute. Dr Tomaz Budefeld, Dr Zeljko Perdiija, and Tadej Tofant, Co-Founders; experts in oncology, molecular diagnostics, and bioinformatics.

Research and Development of the Odnass Test

Odnass Early Cancer Screening Test detects cfDNA directly from plasma using AI-enhanced signal interpretation. No sequencing, no column extraction, minimal equipment, blockchain-secured data loop, and full EMR system integration.

Technologies / Special Know-How

Protected under a provisional Patent covering direct cfDNA detection chemistry, AI/GNN predictive modelling and blockchain technology. Unique bioinformatics architecture and proprietary signal analysis create strong barriers to entry.

Market

The global multi-cancer early detection (MCED) market exceeds US \$150B (CAGR >13%). Odnass targets 60M tests annually at approximately US \$100/test, a potential US \$6B revenue opportunity. Business model: IP licensing or acquisition following proof-of-concept and prototype validation.

Distribution Channels

Strategic licensing to Tier-1 MedTech's (e.g., Roche, Guardant Health, Illumina, Exact Sciences) and partnerships with diagnostic networks for global rollout.

Competition

Galleri (Grail) – ctDNA sequencing, 10–14 days, ~\$950.
Quadrant Shield – ctDNA + AI, 7–10 days, ~\$1,200.
OncoSeek – protein biomarkers, 3–5 days, ~\$145.
Odnass – direct cfDNA + AI/GNN + Blockchain, 3 hours, <\$100.

Financial Projection (Indicative Potential)

Global Potential (Full Scale)	Initial Regional Rollout
Annual Tests: 60 million	Annual Tests: 6 million
Price per Test: US \$100	Price per Test: US \$100
Potential Revenue: US \$6 Billion	Potential Revenue: US \$600 Million
Gross Margin: >70%	Gross Margin: >70%

Quick Facts

Company Name: Odnass Pty Ltd
Contact: Dr Velimir Pajic, CEO
Address: Perth, WA, Australia
Email: velimir.p@odnass.com | admin@odnass.com
Website: www.odnass.com (under construction)
Industry: MedTech / Biotechnology
Patent Estate: AU 2025902937 – Direct cfDNA Detection & AI/GNN Modelling + Blockchain
Financing Sought: US \$1.5M SAFE
Use of Funds: Proof-of-Concept.

Closing Statement

Operational Readiness - Odnass is entering its proof-of-concept phase with validated laboratory infrastructure, patent protection, and a skilled scientific team ready to execute rapid trials, positioning the company for early partnership and commercialization discussions.



Solaris Endovascular, Inc. – Executive Summary (October 2025)

Solaris Endovascular, Inc. is a U.S.-based medical device company developing next-generation **endovascular stent-graft technologies** that overcome the mechanical and biological limitations of current vascular devices. The company's proprietary **electrospun PTFE** platform delivers superior flexibility, strength, and precision, while its **drug-eluting version** introduces controlled **sirolimus** release to inhibit restenosis — the re-narrowing of blood vessels after intervention.

Solaris's mission is to **redefine vascular intervention through durable vessel repair and biologically controlled healing**, improving long-term outcomes in **dialysis access dysfunction** and **peripheral artery disease (PAD)**.

Product Portfolio

Product	Description	Clinical/Regulatory Status
Solaris SX	Self-expanding electrospun PTFE covered stent offering superior radial strength, flexibility, and precision deployment.	CE Mark (MDR) approved and sold in 40 countries . Two completed multicenter trials showing 74% 6-month patency in dialysis access.
Solaris DE	First-in-class sirolimus-eluting covered stent addressing edge restenosis , the last major cause of stent failure.	Phase II DEScover Trial shows 95% 6-month patency with no device-related adverse events.

Clinical Breakthrough – DEScover Trial

- **Design:** 120-patient multicenter randomized study (Solaris DE vs. PTA)
- **Primary Endpoint:** Target Lesion Primary Patency (6 months)
- **Results:** 95% TLPP overall; 100% AVG; 90.9% AVF; no serious AEs
- **Impact:** First-ever data demonstrating effective drug elution from the metal edges of a covered stent — solving edge restenosis and setting a new therapeutic standard.

Market Opportunity

Metric	2024	2030 Projection
TAM (Peripheral Vascular / Dialysis Access Interventions)	\$8.7 B	\$13 B
SAM (Self-Expanding Covered Stents)	\$1.4 B	\$3 B

Drivers: growing dialysis population, global reimbursement coverage, limited competition, and clear clinical differentiation.

Strategic Advantages

- **First drug-eluting covered stent**—unmatched combination of mechanical durability and biological control.
- **Validated technology** with >13,000 Solaris SX units implanted globally.
- **Exclusive worldwide IP rights** acquired from Scitech Medical.
- **Lean, outsourced model** with ISO 13485-certified manufacturing under Solaris QMS.
- **Clear FDA path** via single pivotal PMA study (Solaris SX → Solaris DE).

Next Milestones

- **Q4 2025:** IDE submission for Solaris SX pivotal U.S. trial
- **2026:** Completion of DEScover full enrollment and 12-month data
- **2027–2028:** U.S. PMA submission and commercial readiness
- **2028+:** Global expansion and strategic partnership opportunities

SPACELING®

Your space, where YOU belong



“Social Media is BROKEN and we’re FIXING IT—bringing it back to the way it was meant to be”

SPACELING is **the** disruptive, inclusive social media tech start-up, mission-focused on making a **positive social impact on society**, and driving for a **better & safer digital world**. Tackling global social, online-safety & data privacy challenges, leveraging AI-tech to **protect users’ wellbeing**, and **empowering them with full control** of their privacy, data, and digital experience. Building a global community, benefiting users with a safe, innovative & immersive 3D social media experience, a **trusted space**, where everyone is valued—and all voices matter.

Leadership Founding Team (all equity holding):

- **Michael Sperling, Co-Founder & CEO:** Four decades of co-founding and leading Startup/SMEs.
- **Dilip Chandar, Co-Founder & CTO:** 17+ years’ experience, Ex-CISCO & SPIRENT techpreneur.
- **Dr. Ricardo Periera, Co-Founder:** Computer scientist, researcher, and tenured AI professor.
- **Dr. Douae Ahmadoun, CAIO:** AI PhD, Ex-THALES & SAFRAN, expert in AI, ML, & Data Science.
- **Dr. Dorota Bayer, Dir. of ML & AI:** Published astrophysicist transitioned to AI/ML.
- **Ilaria Leone, CMO:** 15+ years and dual Master’s social media & digital marketing specialist.

Problems: 83% of people globally believe harmful social media content should be restricted, 67% often encounter hate speech online, 85% worry about the impact of fake news. From negative & toxic feeds to misinformation, fake accounts, unauthorised usage and sharing of personal info., manipulative algorithms aggressively monetising human attention, and global concerns raised by whistleblowers, governments, and everyday users alike, social media is harming the wellbeing of its users.

Solutions: A platform built for positive social impact: With a zero-tolerance policy toward toxicity, deploying user-centric algorithms, leveraging AI-tech to power moderation & fact-checking—all backed by a lean & well-trained human team. SPACELING’s putting control of privacy, data, & online experiences back in the hands of its users, via a plethora of privacy, data-sharing, and ads control user-settings. A unique 3D universe with both business & leisure features in one space – eliminating the frustrating need to juggle multiple apps, and in-line with SPACELING’s ethical & fairness ethos, users can even benefit from sharing in the ads profit-pot.

Market Size: TAM: **\$1.04T** Digital Advertising + Social Media, with 5.5B global Internet users.

SAM: **\$252B** Social Media Market Value, with 5.2B global Social Media Users.

SOM: **\$5.2B / 100M users**—a modest **2% penetration** of the SAM (Yr-5 KPI).

Target Market: SPACELING is global and suitable for everyone, regardless of age, gender, race, or belief. Initially, marketing efforts will be focused on young to middle-aged professionals aged 25 - 55 who already use social media regularly (best responsive audience during test campaign).

Go-To-Market Strategy: SPACELING’s go-to-market strategy encompasses Paid Ads (Meta, TikTok, etc.), Influencers, Content Marketing (blogs, emails, SEO, organic social), & Social Proof (reviews, early access community testimonials).

Competition: There are numerous social media platforms around (Meta, X, etc.), but NONE share SPACELING’s commitment to creating an inclusive & welcoming community, within a toxic-free environment, nor do they share SPACELING’s hybrid business model. Although some (e.g., Bluesky & Spill) share parts of this vision, their niche and often narrow offerings, mean a limited audience, while larger platforms consistently fail to protect user interests, harm wellbeing, and are often in the news for all the wrong reasons.

Business Model: SPACELING® is supported by a robust hybrid B2B/B2C financial model and business plan, combining SaaS subscriptions, marketplace commissions, premium upgrades, and advertising revenue streams—with a realistic ARPU of \$30. The model projects moving into the “black” during Yr-3 and has prices ranging from \$0 - \$49 per user / month.

Company Name: SPACELING® LTD

Incorporated: Sep 2019, UK

Address: International House, 64 Nile Street, London, N1 7SR, **United Kingdom**

Website: www.spaceling.com

Bank: Monzo Bank

Law Firm: Veale Wasbrough Vizards LLP

Accountants: Ellacotts LLP

Contact: Michael Sperling—Co-Founder & CEO

Email: michael@spaceling.com

Phone: +44 (0)7818 408757

Industry Verticals: SocialTech, Social Media, Social Networking, Media & Content, Consumer Internet, Social Impact—and **Horizontals;** SaaS, Marketplace & Wellbeing.

Development Stage & Traction: MVP 1.0 with AI-powered solution for moderation & fact-checking, and 3D EXPLORE feature. UX/UI designs, Architectural plan & AI/ML Blueprints, towards BETA. 3D Website (early POC), long-term partnerships, & cross-jurisdictional trade marks—and **early adopter waitlist of ~7,000**.

Monthly Burn Rate: Currently **\$10-12K**.

Pre-Money Valuation: Discounted at **\$17M**.


Audit: Due Diligence & Valuation carried out independently by “Finro Financing Consulting”

Deal Terms: SEED Round | **18% A-ORDS** | Initial SEED round closing 27th March 2026.

Previous Funding: **\$65K** Pre-SEED (+ a \$200K pledge, declined), and “skin in the game” with **>\$650K** self-funding.

The ASK: Seeking to raise **\$3.8M SEED** to support BETA platform development, user acquisition, & OpEx needs—**15-month runway**.

Exit Strategy: Acquisition by suitable global techs




Financial Projection (USD\$ / Millions)	Year 1	Year 2	Year 3	Year 4	Year 5
Number of Users (MAU KPI):	100K	3M	20M	50M	100M
Revenue:	n/a	4.1	174.7	918.4	2,983
GPM %	n/a	93%	88%	86%	85%
EBITA:	(2.8)	(10.0)	12.6	301.2	1,446
Net Profit (after 25% Corp. Tax & Int.):	n/a	(11.7)	6.0	218.5	1,066
Cum. Dividends @ 80% of Net :	n/a	n/a	4.8	179.6	1,032.8

PARTNERS



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at amillin@shulmanrogers.com.



REFRACTION [@refractionpt](#)

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND [@UMD_Dingman](#)

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."



KEIRETSU FORUM [@KeiretsuAngels](#)

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.

PARTNERS



FITCI – FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Frederick, MD, and 52 client companies.



THE BALTIMORE ANGELS @baltimoreangels

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.



MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



STARTUP GRIND-COLUMBIA, MD @StartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.



ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.

PARTNERS



JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS @Hoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



RYAN & WETMORE, P.C. @RyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



**ENTERPRISE TRANSFORMATION SOLUTIONS
INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1**

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



THANK YOU TO OUR PREP TEAM



MICHAEL HANSON
Consultant
Optimum Dynamics LLC



LAURA HILL
Chief of Staff
Bentley



INES LEBOW
CEO
Enterprise Transformation
Solutions



MARISSA LEVIN
CEO
Successful Culture
International



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

SPONSORS



KEIRETSU



FORUM



ROBERT H. SMITH
SCHOOL OF BUSINESS

DINGMAN CENTER
FOR ENTREPRENEURSHIP



Entrepreneurs'
Organization



Cybersecurity
Association



MARYLAND
TECH COUNCIL
ADVANCING LIFE SCIENCES AND TECHNOLOGY



美西玉山科技協會
Monte Jade West
Science and Technology Association



U.S. INTERNATIONAL
DEVELOPMENT CENTER

MIT Alumni Angels of
Washington DC



GEORGETOWN
Entrepreneurship
Serving all of Georgetown University
from the McDonough School of Business



CITRINE
ANGELS



FOUNDER INSTITUTE



ETS Enterprise Transformation Solutions™

Register for our upcoming events

In-Person Event

Nov. 18, 2025
Baltimore, MD



In-Person Event

Dec. 16, 2025
McLean, VA



In-Person Event

Jan. 11, 2026
San Francisco, CA



In-Person Event

Feb. 5, 2026
Baltimore, MD





VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**300k business
leaders**
in our Community

SCAN HERE FOR
THE IN-PERSON
BROCHURE:



SCAN HERE FOR
THE VIRTUAL
BROCHURE:



Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**



**View the full
brochure**

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

● **SUPERCARGE YOUR
RAISE WITH OUR**

CROWDFUNDING SERVICES

We combine high-impact messaging, investor psychology, and access to our unique community of over 315,000 accredited and retail investors, business leaders, and influencers.

WHAT WE OFFER

- ✓ **Dedicated Email Blasts**
- ✓ **Multi-Email Drip Campaigns**
- ✓ **Campaign Strategy Support**
- ✓ **Video and Page Feedback**
- ✓ **Live Investor Engagement Opportunities**



**View the full
brochure**

CONNECT with us!

